Paris - Delayed Quote ? EUR PHAXIAM Therapeutics S.A. (PHXM.PA) Follow Compare 1.6640 -0.0040 (-0.24%) At close: November 1 at 4:50 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024 Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056 226 9326 226 683May 31, 20246 075 1056 226 9896 226 740July 1, 20249 980 66810 GlobeNewswire ? 22 days ago PHXM.PA -0.24% PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study A Phase 2 study sponsored by Assistance Publique – H?pitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)Evaluation of the efficacy of a local treatment with PHAXIAM’s anti-S. aureus phages added to the standard treatment by surgery and antibiotics 80 patients to be enrolled in 27 French clinical centersValidation of the study protocol by the ANSM expected in H1 2025 Lyon (France), October 9, 2024 – 06:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471 GlobeNewswire ? 23 days ago PHXM.PA -0.24% PHAXIAM Provides Business and Financial Update For the First Half of 2024 Continuous commitment to create a global leader in phage therapies to treat severe and resistant bacterial infections Ambitious development strategy on track with clear objectives set for the Prosthetic Joint Infections (PJI) strategic program Clinical readout expected before end of year 2024, including Updated Compassionate real life clinical data and PhagoDAIR pilot studyImminent Filing of Investigational New Drug Application (IND) in US and Clinical Trial Application (CTA) in Europe for GLORI GlobeNewswire ? last month PHXM.PA -0.24% Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056 GlobeNewswire ? 3 months ago PHXM.PA -0.24% Results of the Combined General Meeting of 28 June 2024 Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announces the results of the shareholder vote following the Combined General Meeting held today, 28 June 2024, at the head office, located 60 avenue Rockefeller, 69008, Lyon. The shareholders approved all the resolutions on which the Board of Directors recommended a favo GlobeNewswire ? 4 months ago PHXM.PA -0.24% PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024 Lyon (France) and Cambridge (MA, US), 7 June 2024 - 5.45pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced the availability of preparatory documents for the Combined General Meeting of 28 June 2024. Shareholders of PHAXIAM Therapeutics are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company's registered office at GlobeNewswire ? 4 months ago PHXM.PA -0.24% Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056 GlobeNewswire ? 4 months ago PHXM.PA -0.24% PHAXIAM provides Business and Financial Update for the First Quarter of 2024 PHAXIAM provides Business and Financial Update for the First Quarter of 2024 Webinar (in French) today, May 15, 2024, at 6.00 pm CEST Accelerated clinical efforts to roll-out PHAXIAM’s strategy in order to create a global phage-therapy leader in high-value indicationsCash and cash equivalents of €5.8 million, as of March 31, 2024 Lyon (France) and Cambridge (MA, US), May 15, 2024, at 5.45 pm CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innova GlobeNewswire ? 5 months ago PHXM.PA -0.24% Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056 GlobeNewswire ? 5 months ago PHXM.PA -0.24% PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus The study plans for the enrolment of 12 patients in 5 French clinical centersFirst study results expected in Q3 2024This study will enable an evaluation of the intravenous administration of phages, particularly adapted to targeting indications with very high medical stakes. Lyon (France) and Cambridge (MA, US), April 15, 2024 – 7:30am CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the enrolment of the 1st patient in the phase 1 clinical study in endocarditis infec GlobeNewswire ? 6 months ago PHXM.PA -0.24% Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689 (1) Gross voting rights GlobeNewswire ? 6 months ago PHXM.PA -0.24% PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD) Lyon (France) and Cambridge (MA, US), 5 April 2024 – 6:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced that it has filed its Universal Registration Document with the Autorité des Marchés Financiers (AMF) in France for the financial year ending 31 December 2023.This document, including the annual financial report and the Board of Directors' report on corpora GlobeNewswire ? 6 months ago PHXM.PA -0.24% PHAXIAM Announces 2023 Full-Year Results and Provides Business Update Conference call and webcast (English) on Thursday, March 21, 2024 at 9:30am ET / 2:30pm CET Ongoing clinical efforts boding well to create a global phage-therapy leader in high-value indications First clinical results of the Phase 1 study in Endocarditis Infections expected in the second half of 2024Plan to launch the 1st global Phase 2 Proof-Of-Concept study in Prosthetic Joint Infections (PJI) in early 2025, leveraging on PhagoDAIR study Compassionate access program continues to gain momentum GlobeNewswire ? 7 months ago PHXM PHXM.PA -0.24% PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective. Each ADS represents one ordinary share of the Company. The Company will file a For GlobeNewswire ? 7 months ago PHXM Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024 Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) & Nasdaq Global Select Market in the United-States (Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rig GlobeNewswire ? 7 months ago PHXM PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading marketNasdaq delisting will significantly reduce PHAXIAM’s cash utilization and enable the Company to focus its financial resources on key development and value milestones Lyon (France) and Cambridge (MA, US), February 20, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical com GlobeNewswire ? 8 months ago PHXM Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) & Nasdaq Global Select Market in the United-States (Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753 (1) Gross voting rights numbe GlobeNewswire ? 8 months ago PHXM PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024 Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024. Cash position as of December 31, 2023 As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million). With th GlobeNewswire ? 9 months ago PHXM Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2023 Monthly information related to total number of voting rights and shares composing the share capital _ December 31, 2023 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) & Nasdaq Global Select Market in the United-States (Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rig GlobeNewswire ? 9 months ago PHXM Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023 Monthly information related to total number of voting rights and shares composing the share capital _ November 30, 2023 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) & Nasdaq Global Select Market in the United-States (Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rig GlobeNewswire ? 10 months ago PHXM Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is CAC 40 Return PHXM.PA CAC 40 YTD -63.83% -1.78% 1-Year -63.02% +7.60% 3-Year -93.55% +8.47%
